Literature DB >> 19078454

Neck mass in a rheumatoid arthritis patient taking etanercept.

J D Carter1, K S Kanik, J Valeriano.   

Abstract

A 60-year-old Caucasian woman with a history of rheumatoid arthritis and a remote history of a post-traumatic splenectomy developed a serious head and neck infection 11 weeks after beginning therapy with etanercept. The patient required incision and drainage of a neck abscess and 2 weeks of i.v. antibiotics to achieve complete recovery. Her etanercept was also discontinued. The causative organism was Streptococcus constellatus, which is a member of the group of encapsulated organisms known as S. intermedius. A normal functioning spleen as well as tumor necrosis factor are both necessary to ward off encapsulated bacteria. Patients who have had a splenectomy and are then started with etanercept may be especially prone to infections with encapsulated organisms, such as streptococcus.

Entities:  

Year:  2000        PMID: 19078454     DOI: 10.1097/00124743-200004000-00004

Source DB:  PubMed          Journal:  J Clin Rheumatol        ISSN: 1076-1608            Impact factor:   3.517


  2 in total

Review 1.  Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety.

Authors:  K L Hyrich; A J Silman; K D Watson; D P M Symmons
Journal:  Ann Rheum Dis       Date:  2004-07-08       Impact factor: 19.103

2.  Fatal group A Streptococcus purpura fulminans in a child receiving TNF-α blocker.

Authors:  Christian Renaud; Philippe Ovetchkine; Patricia Bortolozzi; Claire Saint-Cyr; Bruce Tapiero
Journal:  Eur J Pediatr       Date:  2010-11-10       Impact factor: 3.183

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.